Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

BlackThorn Therapeutics  Acquired by Neumora Therapeutics (2021  amount undisclosed )

780 Brannan Street
So. San Francisco, CA 94103
USA
Website Company Summary Management Team
Management

President/COO/Operations: Bill Martin
General Management: Atul R. Mahableshwarkar (7/11/2017) ; Laura G. Hansen (3/31/2019) ; Annette Madrid ; Jane Tiller (3/31/2019)
Board

Outside board: (May no longer be on the board) Matthew K. Fust (Onyx Pharmaceuticals Former CFO) Kristina Burow (ARCH Venture Partners Managing Director) Paul L. Berns (Anacor Pharmaceuticals) Asish K. Xavier (JJDC) Mark Corrigan (BlackThorn Therapeutics Chairman) John MacPhee (The Jed Foundation Executive Director)
Company

Business description: BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. With pathfinderâ„¢, our computational psychiatry platform, our approach is based on generating a quantitative, brain-based understanding of neurobehavioral disorders. These data-driven insights are applied to create treatments targeted to biologically-based subtypes of patients to increase the precision of therapeutic intervention. Our clinical pipeline is designed to restore balance to dysregulated brain circuits and empower individuals with CNS disorders to live better lives.
Capital

Rounds: 3
Recent Fundings: Jun 2019   Jan 2017
Capital raised: 138.0M
Last Round: 76.0M
Ownership: Acquired by Neumora Therapeutics (2021  amount undisclosed )
VCs include: Vertex Ventures Arch Venture PartnersAlexandria Real Estate Equities;  Altitude Life Science Ventures;  Mercury Fund;  Johnson & Johnson Ventures;  Biomatics Capital ;  Premier Partners
Corporate investors: GV ;  Scripps Research

Last Tweets


 

Last Mentions


Overview
Record updated: Oct 2021
Sector: Medical
Year Founded: 2014
Headcount: 26-50 as of Jan 2019
Rounds: 3
Recent Fundings: Jun 2019   Jan 2017
Capital Raised: 138.0M
Last Round: 76.0M
Ownership: Acquired by Neumora Therapeutics (2021  amount undisclosed )